Immune Thrombocytopenia Market
The market size of Immune Thrombocytopenia in 7MM was USD 2527.72 Million in 2017.
The total prevalent population of Immune Thrombocytopenia in the 7MM is estimated to be approximately 184,676 in 2020.
The key players in the Immune Thrombocytopenia market include Octapharma USA, Amgen, CSL Behring, Dova Pharmaceuticals, Rigel Pharmaceuticals, Novartis, Bio Products Laboratory, Takeda, AstraZeneca, Biotest, SK Plasma, Argenx, Kezar Life Sciences, UCB Biopharma, Bristol-Myers Squibb, Principia Biopharma, Protalex and others.
For more detailed information visit:
https://www.delveinsight.com/report-store/immune-thrombocytopenia-market
Precision Medicine
The concept of Precision medicine has been part of healthcare for a very long time, but the rapid progression observed in recent years is quite significant.
Precision medicine can be helpful in providing treatment to a wide variety of diseases such as melanomas, leukaemias, lung and breast cancer.
Apart from the cancerous diseases, precision medicine can also play an important role in prediction and prevention of certain diseases such as Diabetes, Asthma, and Heart disease which are related to the family history of the individuals.
Precision medicine has a promising future. In the coming years, the implementation of artificial intelligence and blockchain technology in the Precision Medicine field is expected to be a game-changer in the management of chronic and life-threatening illnesses.
For more details visit:
https://www.delveinsight.com/blog/precision-medicine/
Hunter Syndrome Market
The Hunter Syndrome Market is expected to increase with a CAGR of 7.5% in 7MM during the study period (2017-2030).
The total diagnosed prevalent population of Hunter Syndrome in 7MM was 1,166 in 2017.
The key players in Hunter Syndrome Market include Takeda, JCR Pharmaceuticals, GC Pharma, Regenxbio, Denali Therapeutics, Sangamo Therapeutics, ArmaGen and others.
For more details visit:
https://www.delveinsight.com/report-store/hunter-syndrome-market
Adrenoleukodystrophy Market
As per DelveInsight, in 2017, the total prevalent population of Adrenoleukodystrophy in the 7MM was 55,242.
A higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries during the study period (2017–2030).
The market size for Adrenoleukodystrophy in the United States was USD 523.26 million in 2017. The market of Adrenoleukodystrophy is expected to experience a significant rise in the coming years.
The key players in the Adrenoleukodystrophy Market include Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris, SOM Biotech and others.
For more information visit:
https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
Immune Thrombocytopenia
The Immune Thrombocytopenia market size in the 7MM was approximately USD 2,527.72 million in 2017. The United States accounts for the largest ITP market size.
Prospective trials, by several pharma companies including Octapharma USA, Amgen, CSL Behring, Dova Pharmaceuticals, Rigel Pharmaceuticals, Zenyaku Kogyo/Biogen Idec, Novartis, Takeda, AstraZeneca, Biotest, GC Pharma, SK Plasma, Argenx, Kezar Life Sciences, UCB Biopharma, Bristol-Myers Squibb, Principia Biopharma, and Protalex, are underway that may be able to enhance the approach and improve overall outcomes in ITP patients in upcoming years.
There are many pipeline therapies under development in the Immune thrombocytopenia market; and with the expected launch of upcoming therapies the ITP market is expected to experience significant growth.
For more detailed information visit: https://www.delveinsight.com/blog/immune-thrombocytopenia-market/
Hunter Syndrome Market
Occurring in approximately 1 in 100,000 to 1 in 170,000 male births, Hunter Syndrome, is an X-linked disorder, of carbohydrate metabolism that occurs almost exclusively in males, with females as the carriers of the diseases.
The HunterSyndrome Market is expected to experience a positive push in the coming years with a CAGR of 7.5% for 7MM.
The key players in the Hunter Syndrome Market include JCR Pharmaceuticals Co Ltd, REGENXBIO Inc., GC Pharma, Denali Therapeutics, Sangamo Therapeutics, Inc., ArmaGen, Inc. and others.
For more details visit:
https://www.delveinsight.com/blog/hunter-syndrome-market/
#pharmaceuticals #healthcare #lifesciences #genetics #MPSII #biotechnology #medicalsciences #rarediseases #mucopolysaccharidosis
Catheter-Related Bloodstream Infection (CRBSI) Market
The market size of Catheter-Related Bloodstream Infection in the 7MM was USD 694.7 Million in 2017.
As per DelveInsight’s analysis, the total incident population of Catheter-Related Bloodstream Infection (CRBSI) was found to be 6,69,393 in 7MM in 2017.
Competitive landscape, increasing research & development activities, and cost-effectiveness of emerging therapies are some of the key factors expected to drive the Catheter-Related Bloodstream Infection Market in the upcoming years.
The key players in the Catheter-Related Bloodstream Infection market include CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, Citius Pharmaceuticals and others.
For more detailed information, visit:
https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
Lamellar Ichthyosis Market Insight and Market Forecast
Lamellar Ichthyosis (LI) is a type of autosomal recessive congenital Ichthyosis (ARCI), which is a clinically and genetically heterogeneous group of dermatological scaly skin disorders.
Infants affected with LI are born encased in a hyperkeratotic translucent membrane, known as collodion baby, and within 2 weeks develop large, thick, brownish lamellar scales with minimal erythema. Additionally, LI is associated with crumpled ears, alopecia, eclabium, and ectropion.
Total Prevalence of Inherited Ichthyosis in France was estimated at 13.3 per million people and the prevalence of lamellar Ichthyosis was 4.5 per million people.
In a study conducted in Japan with 220 patients treated for ARCI and Ichthyosis syndromes, 95 patients were observed with Nonbullous Congenital Ichthyosiform erythroderma, 30 with lamellar Ichthyosis, and 15 with harlequin Ichthyosis (Kurosawa et al.)
A study conducted in Spain on 144 patients with ARCI has shown that among these patients, 62.5% had classic Lamellar Ichthyosis and 30.6% had congenital Ichthyosiform Erythroderma (Martín et al).
The Age-standardized Prevalent cases of Lamellar Ichthyosis (LI) recorded in the United States is proportionally decent.
The lowest prevalence population of Lamellar Ichthyosis (LI) was recorded in Japan (in 7MM).
For more details visit:
https://www.delveinsight.com/report-store/lamellar-ichthyosis-market
Familial Hypercholesterolemia Market Insight and Market Forecast
Familial hypercholesterolaemia (FH), is an autosomal dominant genetic disorder being characterized by the severe hypercholesterolaemia along with cholesterol deposits in tendons and premature heart disease. FH further classified into two homozygous and heterozygous forms.
The estimated overall US prevalence of probable/definite FH was 0.40% or 1 in 250. FH prevalence in the US is varied by age, being least common in 20 to 29-year-olds and most common in 60 to 69-year-olds.[Sarah D. de Ferranti et al. (2016)]
The lowest incident population of FH was recorded in Japan (in 7MM)
United States has the highest percentage of incident diagnosed & treated patients in 7MM
Spain has consistently shown lowest diagnosed & treated population among EU5 Countries
Among the FH patients, females show higher proportion of incidence of FH as compared to males in the 7MM
According to the estimates provided by the National Institute for Health and Clinical Excellence, the reported prevalence of heterozygous familial hypercholesterolaemia in the UK population is estimated to be 1 in 500.
For more details visit:
https://www.delveinsight.com/report-store/Familial%20Hypercholesterolemia%20-%20Market%20Insight
Dravet Syndrome Market Insight and Market Forecast
According to the Dravet Syndrome Foundation, Dravet syndrome (DS) is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures.
The Signs and Symptoms of the disease involve seizures, ataxia (balance problems), motor impairment, cognitive impairment, behavioral problems, infections, bone problems, and heart rhythm irregularities.
As per DelveInsight’s estimates, the United States accounted for the maximum number of DS patients with 20,731 cases in 2017 followed by Germany with 2,896 cases.
DelveInsight estimates suggest that Missense mutation was found to have the highest number of incident cases among the DS patient population in the US.
According to the paper titled as “Mortality in Dravet syndrome: A review” written by Shmuely S et al. 2016 nearly ~73% of the patients die before the age of 10 years. Sudden unexpected death) in epilepsy (SUDEP was the leading cause of death (~49%) followed by status epilepticus (~32%).
For more information visit:
https://www.delveinsight.com/report-store/dravet-syndrome-market
Alpha Antitrypsin Deficiency Market Insight and Market Forecast
Alpha Antitrypsin Deficiency is the most common hereditary disorder in which the body is unable to produce sufficient amounts of Alpha-Antitrypsin (AAT) protein. Alpha-Antitrypsin (AAT) protein plays an important role in protecting organs of the body such as liver and lungs from the harmful effects of proteolytic enzymes such as neutrophil elastase. Thus, AATD leads to increased risk of developing a liver disease like Cirrhosis, as well as lung diseases such as Emphysema and Chronic Obstructive Pulmonary Disease (COPD) and Panniculitis.
As per DelveInsight estimates, total prevalent population of AATD in 6 major markets was found to be 1,835,647 in 2017
Among the EU5 countries, Germany has the highest prevalent population of AATD with 34,345 cases, followed by the United Kingdom, which has a prevalent population of 27,930 in 2017.
Market Size of Alpha antitrypsin deficiency (AATD) in the 6MM was found to be USD 992 million in 2017
Men and women are equally affected by Alpha Antitrypsin Deficiency
The United States accounts for the largest AATD market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain). Among EU5 countries, Germany had the highest market size, while Spain had the lowest market size of ASD.
DelveInsight Analysts have observed the population with PISS allele to have the highest numbers, followed by PISZ. However, the most prevalent type of deficient allele associated with AAT Deficiency is the Z allele.
For more detailed information visit:
https://www.delveinsight.com/report-store/alpha-antitrypsin-deficiency-market
Wearable Technology To Prevent COVID-19 Progression
COVID-19 is here and is not vanishing anytime soon from our lives as suggested by health bodies, scientists, and researchers. To address the given situation governments, tech companies, hospitals and research institutes are working in collaboration to overcome the current crisis.
Tech Companies from their end are providing a wide range of smart solutions to track and monitor the virus transmission.
Some wearable technology applications such as Safespacer (IK Multimedia), BioButton (BioIntelliSense, Inc), SafeZone (KINEXON), and others are playing a crucial role in mitigating the transmission of COVID-19.
For more detailed information visit:
https://www.delveinsight.com/blog/covid-19-and-wearable-technology/
Metabolic Acidosis Market
According to DelveInsight, the therapeutic market of Metabolic Acidosis in 10 emerging markets generated USD 484 Million in 2017 and is expected to change in the forecast period 2017–2030.
The total prevalent cases of Metabolic Acidosis in 10 emerging markets was found to be 1,97,26,410 in 2017.
The key players in the Metabolic Acidosis market include Tricida, Advicenne Pharma and others.
For more information visit: https://www.delveinsight.com/report-store/metabolic-acidosis-market
Progressive Supranuclear Palsy Market
According to DelveInsight, the market size of Progressive Supranuclear Palsy in 7MM was found to be USD 10.54 Million in 2017 and is expected to increase during the study period (2017-2030).
In 2017, the total prevalent cases of Progressive Supranuclear Palsy were found to be 98,498 in seven major markets.
The key players in Progressive Supranuclear Palsy market include AlzProtect, UCB Biopharma, Asceneuron Therapeutics, TauRx Pharmaceuticals and others.
For more detailed information visit: https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market
Familial Chylomicronemia Syndrome Market
The total prevalent population of Familial Chylomicronemia Syndrome (FCS) in the 7MM was found to be 5,801 in 2017.
The therapeutic market of Familial Chylomicronemia Syndrome in seven major markets was found to be USD 1.0 Million in 2017 which is expected to increase during the study period (2017–2030).
The key players in the Familial Chylomicronemia Syndrome Market include Akcea Therapeutics, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Amryt Pharma and others.
For more information visit:
https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market
Duchenne Muscular Dystrophy Market
The Duchenne Muscular Dystrophy Market Size (DMD Market) in the 7MM was found to be USD 266.06 Million in 2017, during the study period (2017-2030).
Duchenne Muscular Dystrophy (DMD), approximately affects 1 in 3,500 male births globally. Moreover, Duchenne Muscular Dystrophy prevalence in the 7MM (The US, EU5, and Japan) was found to be approximately 31,386 in 2017 with the diagnosed prevalence of 26,678.
The key players in the Duchenne Muscular Dystrophy Market include like Sarepta Therapeutics, Santhera Pharmaceuticals, Catabasis Pharmaceuticals, Hoffmann-La Roche, FibroGen, Antisense Therapeutics, REVERAGEN BIOPHARMA LIMITED, Italfarmaco, Nobelpharma America, Pfizer, Cumberland Pharma and many others.
For more detailed information visit:
https://www.delveinsight.com/blog/duchene-muscular-dystrophy-market/
Acute Kidney Injury Market
As per DelveInsight Business Research LLP, the Acute Kidney Injury Market size in the 7 MM was observed to be USD 4,082.95 Million in 2017.
The United States accounted for the maximum Acute Kidney Injury cases among 7MM countries with an incidence of 895,078 in 2017. On the other hand, Japan accounted for the least share of Acute Kidney Injury Incidence.
Emerging therapies in the Acute kidney injury pipeline look promising as several companies such as Angion, Atox Bio, Exponential Biotherapies, Inc., Orion Pharma Ltd, Astellas Pharma US, MediBeacon Inc., AM-Pharma, Quark Pharma, and Pharming Technologies are proactively looking to foster the Acute kidney injury market through their novel molecules and R&D.
For more details visit: https://www.delveinsight.com/blog/acute-kidney-injury-market/
Recent pharma happenings
Merck supports Peloton Therapeutics with positive kidney cancer data
Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising.
Thermo Fisher, WuXi and Mayo Clinic to develop COVID-19 antibody test
Thermo Fisher Scientific is developing its COVID-19 antibody test through an ongoing, three-way partnership with WuXi Diagnostics and the Mayo Clinic, and slates to search for international authorizations for the test over the upcoming weeks.
Johnson & Johnson’s anti-BCMA CAR-T sweeps multiple myeloma aside
Johnson & Johnson’s BCMA-targeting CAR-T therapy cast out tumors in 86% of patients with advanced multiple myeloma in a phase 1b study.
Tafinlar-Mekinist combo of Novartis receives a boost
Tafinlar and Mekinist with experimental PD-1-blocking Spartalizumab cast out tumors in 44% of patients with advanced melanoma, as shown in phase 3 data.
For more details visit: https://www.delveinsight.com/blog/recent-pharma-happenings-for-novartis-thermo-fisher-merck-wuxi/
LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035
According to DelveInsight, the LAG-3-Next Generation Immunotherapy market is expected to generate USD 3,421 Million in the year 2035 with a significant CAGR in the forecast period. NSCLC will occupy the major market share that is 98.81% by 2035.
Launch of potential upcoming therapies, the addition of personalised drug therapies with combination therapies for efficacy enhancement, increased funding for R&D expense, understanding of disease and pathogenesis are some of the key factors expected to drive the LAG-3-Next Generation Immunotherapy market in upcoming years.
The key players in LAG-3-Next Generation Immunotherapy market include MacroGenics, Zai Lab, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, Regeneron, Xencor, Incyte Biosciences, Agenus, Roche, GlaxoSmithKline, Innovent Biologics (Suzhou) Co. Ltd. and others.
For more information visit: https://www.delveinsight.com/report-store/LAG-3-next-generation-immunotherapy-competitive-landscape
Security Breach In Healthcare Sector
The healthcare sector over the past few years has registered a higher number of data breaches as compared to other industries.
The higher monetary gains out of the patient's medical and personal information is the main reason for higher breaches.
Data breach and illegal or Unethical extraction of any form of data can have serious consequences and impact the lives of people negatively.
With the advancement in technology, a large number of patients are likely to opt for online healthcare service in upcoming years. With the increasing demand, the risk of new and emerging cyber-attack is also expected to increase.
For more details visit:
https://www.delveinsight.com/blog/security-breach/
Joined Feb 2020
